奈力生醫共同創辦人、牟中原院士，榮獲由國際介觀結構材料協會理事會（Council of the International Mesostructured Materials Association）頒發的最高榮譽獎項 —「IMMA Award」. | We are proud to announce that our company co-founder, Prof. Chung-Yuan Mou, was officially awarded the 「IMMA Award」, presented by the Council of the International Mesostructured Materials Association

「2026 NBRP DEMO & PITCH DAY」由中央研究院生醫轉譯研究中心與財團法人生物技術開發中心共同主辦，旨在建構全方位的生醫創新樞紐，促進生醫創新技術與產業資源的交流與鏈結。本次活動匯聚多家具高度發展潛力的生醫團隊，展示其創新技術、產品開發成果及商業發展潛力。奈力生醫於眾多優秀團隊中脫穎而出，榮獲「潛力團隊獎」，充分肯定公司在前沿技術、創新產品及國際市場發展方面的潛力。

NTT Biopharma’s proprietary Mesoporous Silica Nanoparticle (MSN) Drug Delivery Platform has been recognized with the 22nd National Innovation Award, in acknowledgment of its innovative value in overcoming critical drug delivery barriers and addressing significant unmet medical needs. | 奈力生醫(NTT Biopharma)自主研發的「中孔洞二氧化矽奈米粒子(Mesoporous Silica Nanoparticle, MSN)藥物傳輸平台技術」在突破藥物傳輸瓶頸與解決未滿足醫療需求上的創新價值，榮獲第22屆國家新創獎—企業新創獎肯定。

Despite advancements in nanomedicine for drug delivery, many drug-loaded nanoparticles reduce tumor sizes but often fail to prevent metastasis. Mesoporous silica nanoparticles (MSNs) have attracted attention as promising nanocarriers. Here, we demonstrated that MSN-PEG/TA 25, with proper surface modifications, exhibited unique antimetastatic properties.

Mesoporous silica nanoparticles (MSNs) represent a promising avenue for targeted brain tumor therapy. However, the blood–brain barrier (BBB) often presents a formidable obstacle to efficient drug delivery. This study introduces a ligand-free PEGylated MSN variant (RMSN25-PEG-TA) with a 25 nm size and a slight positive charge, which exhibits superior BBB penetration.

While temozolomide (TMZ) has been a cornerstone in the treatment of newly diagnosed glioblastoma (GBM), a significant challenge has been the emergence of resistance to TMZ, which compromises its clinical benefits. Additionally, the nonspecificity of TMZ can lead to detrimental side effects. Although TMZ is capable of penetrating the blood–brain barrier (BBB), our research addresses the need for targeted therapy to circumvent resistance mechanisms and reduce off-target effects. This study introduces the use of PEGylated mesoporous silica nanoparticles (MSN) with octyl group modifications (C8-MSN) as a nanocarrier system for the delivery of docetaxel (DTX), providing a novel approach for treating TMZ-resistant GBM.

今(6)日，利基型藥廠台灣神隆(1789)與專精奈米藥物傳輸技術的奈力生醫(Nano Targeting & Therapy, NTT)宣布，雙方已簽定技術轉讓協議，針對利用 「中孔洞二氧化矽奈米體(mesoporous silica nanoparticle, MSN) 傳遞多西紫杉醇 (docetaxel)治療腦癌」技術，建立合作發展計畫。該項奈米體藥物傳遞技術平台擁有多項創新優勢，可望提高藥物的療效，為目前眾多尚待克服的治療限制帶來曙光。

泰福-KY(6541)於3/25日宣布，將與奈力生醫合作，並結合國立台灣大學曾宇鳳教授, 共同開發多項利用重組蛋白或寡肽作為抗原, 用於預防或治療COVID-19冠狀病毒疫苗。 台灣泰福團隊利用多年來蛋白質生物藥開發經驗，以基因技術及微生物細胞篩選穩定表達 COVID-19 病毒抗原重組蛋白的菌株，加以純化後預計可在近期提供給奈力生醫進行後續奈米傳輸技術包裹，並啟動體外及動物實驗。